Hims plans to offer testosterone replacement therapy, the first time the telehealth company will prescribe a controlled substance.
The company already sells treatments through its app for conditions people would rather not raise at a doctor's office. Testosterone therapy follows the same logic of convenience, but it sits in a different legal category. Reporting on the plan describes an ambition to screen men broadly for low testosterone, which would make testing the front door to the product.
The controlled-substance label is the real change. Federal law classifies testosterone as a Schedule III drug, a tier that carries tighter prescribing and recordkeeping rules than the non-controlled medications Hims has built its business on. A company that has competed on speed and low friction now takes on a product where regulators watch the process more closely.
That makes the operational details the part to follow: how a diagnosis is reached, where blood work is drawn, and how often patients are retested. Low testosterone is a clinical diagnosis tied to lab results, so the quality of the testing step will matter as much as the prescription that follows it.
Hims has so far stayed on the non-controlled side of telehealth. Testosterone moves it onto ground where convenience and compliance have to coexist.